Abstract 1776
Background
Mobile phones and tablets currently represent a significant presence in people’s everyday lives. They enable access to different information and services independent of current place and time. Such widespread connectivity offers significant potential in different app areas including health care. Advancements in mobile technology allow innovative data collection techniques such as measuring time use for the purpose of improving health behavior change interventions.
Methods
The aim of this study is to examine the usage rates of healthcare users and the health content of applications. A total of 707 mobile app were retrieved through a Google and App store for app published between January to April 2019. In this context, all applications were scanned using "cancer", "oncology", and "breast cancer" keywords on these stores. Repetitive applications were removed and research data was obtained. The applications were evaluated by considering their contents, developers and download numbers.
Results
In the Google play store, under the training title of 268 applications, it was found that 76 applications were used to maintain the treatment scheme and plan, and 12 were used for communication purposes. In the app store, it was determined that 235 applications were used for education, 102 for treatment plan and order, and 14 for communication purposes. Educational applications were used for journal, congress, student information, cancer guidelines and patient information. Drug management for treatment regimen and plan was determined to be related to radiological imaging, diet follow-up, symptoms, and nutrition. It was seen that communication applications were used for both patient-patient and physician-patient interaction. It was found that only 8% of the existing applications that the majority of the application developers did not have a healthcare staff established a health care staff.
Conclusions
It can be said that health personnel develop their own systems and provide accurate information to patients through these systems. With the advancement of health technologies, healthy results can be obtained in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract